Retensin Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Indications/Uses Dosage/Direction for Use Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Valsartan

Indications/Uses

HTN. Heart failure (NYHA class II-IV) in patients receiving standard therapy eg, diuretics, digitalis & either ACE inhibitors or β-blockers but not both. Improves survival following MI in clinically stable patients w/ signs, symptoms or radiological evidence of left ventricular failure &/or w/ left ventricular dysfunction.

Click to view Retensin detailed prescribing information

Dosage/Direction for Use

Adult HTN 80 mg or 160 mg once daily. May be increased to 320 mg, or add diuretic if BP is inadequately controlled. Heart failure 40 mg bid. May be titrated to 80 mg & 160 mg bid as tolerated. Max: 320 mg daily in divided doses. Post-MI Initially 20 mg bid as early as 12 hr following MI. Titrate dose to 40 mg, 80 mg & 160 mg bid over next few wk or until 80 mg bid 2 wk after treatment initiation is achieved. Target max dose in 3 mth: 160 mg bid.

Click to view Retensin detailed prescribing information

Administration

May be taken with or without food.

Contraindications

Hypersensitivity. Concomitant use w/ AIIA or ACE inhibitors w/ aliskiren in patients w/ type 2 diabetes. Pregnancy.

Click to view Retensin detailed prescribing information

Special Precautions

Discontinue treatment if angioedema occurs. Patients w/ biliary obstructive disorders. Correct Na &/or vol depletion prior to treatment. Monitor BUN & serum creatinine in patients w/ bilateral or unilateral renal artery stenosis. Perform renal function assessment in patients w/ heart failure or post-MI. Concomitant use w/ ACE inhibitors & β-blockers in patients w/ heart failure; drugs blocking renin-angiotensin system eg, ACE inhibitors or aliskiren. Avoid concomitant use w/ aliskiren in patients w/ severe renal impairment (GFR <30 mL/min). Women of childbearing potential. Not to be used during pregnancy. Lactation. Childn & adolescents <18 yr.

Click to view Retensin detailed prescribing information

Use In Pregnancy & Lactation

Click to view Retensin detailed prescribing information

Adverse Reactions

Dizziness, postural dizziness; hypotension, orthostatic hypotension; renal failure & impairment.

Click to view Retensin detailed prescribing information

Drug Interactions

Increased incidence of hypotension, hyperkalemia & renal function changes w/ other drugs acting on renin-angiotensin system eg, ARBs, ACE inhibitors, or aliskiren. Increased serum K & creatinine w/ K-sparing diuretics (eg, spironolactone, triamterene, amiloride), K supplements, or K-containing salt substitutes or other drugs increasing K level (eg, heparin). Attenuated antihypertensive effect w/ NSAIDs including selective COX-2 inhibitors. Increased serum lithium conc & toxicity. Increased systemic exposure w/ OATP1B1 inhibitors (eg, rifampin, ciclosporin) & MRP2 inhibitors (eg, ritonavir).

Click to view Retensin detailed prescribing information

Description

View Retensin description for details of the chemical structure and excipients (inactive components).

MIMS Class

Angiotensin II Antagonists

ATC Classification

C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Thai FDA Category

Presentation/Packing

Form

Retensin FC tab 160 mg

Packing/Price

10 × 10's

Form

Retensin FC tab 80 mg

Packing/Price

10 × 10's

Retensin

valsartan

Manufacturer:

Unison

Distributor:

Medline

Marketer:

B.Grimm Pharma